FUN-HSC
Financiado
TACKLING FUNCTIONAL MATURATION FOR TRANSPLANTABLE HEMATOPOIETIC STEM CELL GENERATION
Hematopoietic stem cells (HSC) provide a lifelong supply of blood and immune cells. They are a life-saving therapy for leukemia and have recently found broadened applications to gene and cell therapy, against other cancers, geneti...
Hematopoietic stem cells (HSC) provide a lifelong supply of blood and immune cells. They are a life-saving therapy for leukemia and have recently found broadened applications to gene and cell therapy, against other cancers, genetic, autoimmune, and infectious diseases. Nonetheless, practical limitations, such as donor-matching or insufficient cell number render these therapies unfeasible or unsuccessful for many patients. Attempts to overcome these limitations have been unable to create a reliable source of HSC for patients: while we can generate human HSC from pluripotent stem cells (PSC), they resemble early development stages, lacking the functional maturation hallmarks. FUN-HSC aims at identifying core and actionable maturation pathways for HSCs and at defining the contribution of coordinated gene expression by chromatin regulation, using a combination of functional and genetic screening technologies and high-throughput readouts in vitro and in vivo. HSC maturation occurs in the liver during fetal development and confers functional multilineage hematopoiesis ability throughout adulthood. Using single cell omics analysis of human embryonic and fetal tissues, we describe multiple gene programs changing during developmental HSC maturation. This study will lead to candidate cell-intrinsic and niche-dependent instructions, which will be dissected in the context of the fetal liver, by analyzing the cell compartments and their interactions and by combining novel organoid technologies with mouse xenografts to model the fetal liver environment. Ultimately, we aim to identify a strategy that mimics these pathways in vitro to bring the maturation stage of the PSC-derived HSC, to a robustly engraftable and clinically valuable HSC source. Harnessing new knowledge in human HSC biology, cutting-edge genetics and tissue technologies, FUN-HSC will provide great advances in the mission of making and maintaining HSCs in vitro, enabling their full therapeutic potential.
ver más
Duración del proyecto: 61 meses
Fecha Inicio: 2023-11-15
Fecha Fin: 2028-12-31
Fecha Fin: 2028-12-31
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-11-15
HORIZON EUROPE
No se conoce la línea exacta de financiación, pero conocemos el organismo encargado de la revisión del proyecto.
Presupuesto
El presupuesto total del proyecto asciende a
2M€
Líder del proyecto
FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEM...
No se ha especificado una descripción o un objeto social para esta compañía.
199.90K€ |
Participante